Biomedical advances continue to fascinate and befuddle the minds of people everywhere. Sometimes our real-life progression into the realm of science fiction is eerily apparent. One company, Vicor Technologies (VCRT), shows us the limits of predictive science available to us. Their stock has been climbing recently and will likely continue to do so with news of their latest clinical trial having just been released. Despite this climb however volume is still low, perhaps making this stock difficult to purchase or sell in large quantities.

Vicor Stock has been notorious for having large highs and lows over the years. The most recent gain has brought their stock thus far to around $0.80 from close to $0.50. The last few years have seen several such gains and falls, making it quite a good stock for anyone able to predict when the stock will rise or fall. Stock price rose initially due to news that Vicor received a Notice of Allowance. This allowance was for its U.S. Patent Application No. 10/359,363 for a method of treating ischemia through administration of a biologic identified through Vicor's state dependent drug discovery platform. Upon issuance, this patent will provide Vicor with patent protection for methods of using a peptide to treat infarctions, such as cardiac or cerebral infarctions.

Vicor Tech is a bio-technology company focused on the development and commercialization of innovative, non-invasive medical diagnostics using its patented PD2i technology. This technology is based around non-linear algorithm software which attempts to achieve early identification of ‘disease states’ amongst at-risk populations, without the need to use high cost and invasive procedures. Examples of populations in need of such identification include the 12 million at-risk cardiac patients, 23.6 million diabetics and 38 million trauma incidents that exist.

The PD2i is predictive software used in conjunction with equipment used to listen to the heartbeat of an individual. Rather than looking solely at the heart, PD2i uses the interaction between the brain and the heart to see how at risk an individual may be to sudden cardiac arrest. The subtle patterns of the heartbeat are analyzed by the PD2i software over a 20 minute period, where the individual being studied is at rest, performs controlled breathing and Valsalva maneuvers, where one blocks their nose and mouth while attempting to exhale.

This fascinating piece of technology has shown statistical significance in the results for their recent ‘MUSIC’ trial of the software. Wojciech Zareba, M.D. Ph.D. the Principal Investigator at the University of Rochester said, "These results are of major importance for risk stratifying heart failure patients who are eligible for therapy with an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with defibrillator (CRT-D). Currently, only about 30-40% of heart failure patients eligible for this therapy receive devices.” Should this begin to increase the accuracy and rates of eligibility of implants, this technology will become popular quickly. Not only will lives be saved because of it, but there is also money to be made from it. The more patients who can receive an implant, the more a hospital will be paid, making this a double incentive to introduce this technology.

Investors have yet to react strongly to the news of this morning’s clinical trial results, making this an excellent potential opportunity. On the other hand since stock prices have risen sharply recently, investors may be shying away from jumping onto a stock that may have already peaked.